With many drugs in pharmaceutical industry pipelines showing solubility limitations, formulation of new drug candidates can be complex. This webinar describes approaches that streamline formulation and technology selection for compounds with low aqueous solubility and oral bioavailability. This compound-driven approach carefully matches the characteristics of the active ingredient and the target product profile to the best technology. An overview is provided of common bioavailability-enhancing technologies, including salts, polymorphs, cocrystals, nanocrystals, amorphous dispersions, and lipids. Also covered is the array of in vitro tests that can be used to evaluate bioavailability-enhancing formulations. Finally, three case studies are presented demonstrating the effectiveness of the approach in real-life application.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.